Journal article
Usefulness of Transient and Persistent No Reflow to Predict Adverse Clinical Outcomes Following Percutaneous Coronary Intervention
William Chan, Dion Stub, David J Clark, Andrew E Ajani, Nick Andrianopoulos, Angela L Brennan, Gishel New, Alexander Black, James A Shaw, Christopher M Reid, Anthony M Dart, Stephen J Duffy
AMERICAN JOURNAL OF CARDIOLOGY | EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC | Published : 2012
Abstract
The no reflow phenomenon is reported to occur in >2% of all percutaneous coronary interventions (PCIs) and portends a poor prognosis. We analyzed data from 5,286 consecutive patients who underwent PCI from the Melbourne Interventional Group (MIG) registry from April 2004 through January 2008 who had 30-day follow-up completed. Patients without no reflow (normal reflow, n = 5,031) were compared to 255 (4.8%) with no reflow (n = 217 for transient no reflow, n = 38 for persistent no reflow). Patients with transient or persistent no reflow were more likely to present with ST-elevation myocardial infarction (MI) or cardiogenic shock (p <0.0001 for the 2 comparisons). They were also more likely to..
View full abstractGrants
Funding Acknowledgements
[ "The Melbourne Interventional Group acknowledges unrestricted educational grant funding from Abbot Vascular, AstraZeneca, Biotronik, Boston-Scientific, Bristol-Myers Squibb, CSL, Johnson and Johnson, Medtronic, Pfizer, Schering-Plough, Sanofi-Aventis, and Servier.", "Dr. Chan is supported by scholarships from the National Health and Medical Research Council (NHMRC) of Australia, Canberra, ACT, Australia and GlaxoSmithKline. Dr. Duffy's work is supported by an NHMRC of Australia Program Grant. The work of Dr. Reid, Ms. Brennan, and Dr. Andrianopoulos is supported by an NHMRC of Australia Program Grant." ]